Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Lung Neoplasms 3Melanoma 2Kidney Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Thymoma 1Small Cell Lung Carcinoma 1Precancerous Conditions 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Follicular 1Lymphoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Genetic Diseases, Inborn 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Melphalan 3sargramostim 1romidepsin 1montanide ISA 51 1keyhole-limpet hemocyanin 1detox adjuvant 1Waiting Lists 1Thalidomide 1Radiosurgery 1Radiation 1Leucovorin 1Ketoconazole 1Interleukin-2 1Floxuridine 1FANG vaccine 1Docetaxel 1Alendronate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Genetic Diseases, Inborn × FANG vaccine × Clear all
NCT00019097 2024-03-04

Vaccine Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms, Genetic Diseases, Inborn, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡